Evidence map›Paper›PMID 30038521›Full record

ArticleCancer management and research2018

Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer.

Flavia Cochera, Daniel Dinca, Diana Aurora Bordejevic, Ioana Mihaela Citu, Adelina Marioara Mavrea, Minodora Andor, Mihai Trofenciuc, Mirela Cleopatra Tomescu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 9 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 9 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update.Journal of cardiovascular development and disease · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Flavia Cochera *Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Daniel Dinca *Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Diana Aurora BordejevicCardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Ioana Mihaela CituCardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Adelina Marioara MavreaCardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Minodora AndorCardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Mihai TrofenciucCardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Mirela Cleopatra TomescuCardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania, aurora.bordejevic@umft.ro.
Victor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to assess whether nebivolol treatment could have beneficial effects in the prevention of anthracyclines-induced cardiotoxicity. PATIENTS AND

methodsOur prospective study included 60 women, mean age 52.6±13 years, with HER2 negative breast cancer, scheduled to undergo treatment with doxorubicin. The patients were randomly divided into two groups: the treatment group (n=30) which received nebivolol 5 mg once daily for the duration of chemotherapy and the control group (n=30) without treatment with nebivolol. Cytostatic treatment was performed with doxorubicin 70 mg/m

resultsWe found no significant differences between the two groups regarding baseline clinical and echocardiographic parameters. The two groups reached a similar cumulative dose of doxorubicin. No patient died during the study. None of the patients withdrew from chemotherapy. After six cycles of doxorubicin therapy, the left ventricular (LV) ejection fraction, shortening fraction, and LV diameters changed, but not significantly. Tissue Doppler imaging (TDI) detected in the control group a significant decrease of myocardial velocities, indicating a LV diastolic dysfunction. In the same group, speckle tracking imaging (STI) revealed a statistically significant alteration of the ventricular deformation, which means a decrease in LV systolic function. In the nebivolol treatment group, no significant alterations in the LV systolic and diastolic function were observed.

conclusionThe results of this study show the benefit of new echocardiographic imaging methods such as TDI and STI in the screening of early cardiac dysfunction induced by cytostatic treatment. Nebivolol treatment prevented the occurrence of anthracyclines-induced cardiomyopathy in the short term. In order to confirm these preliminary results, larger studies with a longer follow-up period are required.

Indexed as

breast cancercardioprotectioncardiotoxicitydoxorubicinechocardiographynebivolol

Identifiers

PMID30038521
PMCPMC6053261
OpenAlexW2883206770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.